Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial

SIMPLE SUMMARY: There is no valid consensus regarding follow-up for pancreatic cancer in terms of recommended investigations in routine practice. By analogy with other pathologies, cross-sectional imaging is often performed every 3 months. In addition, the low number of available chemotherapy regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Egea, Julie, Salleron, Julia, Gourgou, Sophie, Ayav, Ahmet, Laurent, Valérie, Juzyna, Béata, Harlé, Alexandre, Conroy, Thierry, Lambert, Aurélien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599967/
https://www.ncbi.nlm.nih.gov/pubmed/36291851
http://dx.doi.org/10.3390/cancers14205068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599967/
https://www.ncbi.nlm.nih.gov/pubmed/36291851
http://dx.doi.org/10.3390/cancers14205068

Ejemplares similares